B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. - Wikidata - wikimedia - TriplyDB

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.

http://www.wikidata.org/entity/Q36778126

about

Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?The Role of Immunotherapy in Multiple Myeloma B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia CAR T Cell Therapy: A Game Changer in Cancer Treatment New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Immunotherapy strategies for multiple myeloma: the present and the future Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma Development of Novel Immunotherapies for Multiple Myeloma Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC.Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.Driving CAR T-cells forward Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.Reassessing target antigens for adoptive T-cell therapy.NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.The development of potential antibody-based therapies for myeloma Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.CAR-T Cell Therapy for Lymphoma.The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.Toxicities of chimeric antigen receptor T cells: recognition and management."Model t" cells: a time-tested vehicle for gene therapy Exploiting the curative potential of adoptive T-cell therapy for cancer.CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma Antibody-modified T cells: CARs take the front seat for hematologic malignancies.Adoptive immunotherapy for cancer.Immunotherapeutic approaches to treat multiple myeloma Adoptive immunotherapy for cancer or viruses.The Tao of myeloma.T cell-based targeted immunotherapies for patients with multiple myeloma.Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?

P2860

Q26740359-AAAE7A4B-399B-4B5D-A28F-0E736B960A82 Q26771144-CE1A1EA5-993D-4A96-AB78-DBEB174DAC54 Q26784444-8B57629F-D679-495C-A607-DEFA6525D4A9 Q26822769-00592433-0A1F-4C3D-AB47-357CF1DB9C4B Q27004421-C467EE79-34D5-4D5C-8C3F-FC6EE293DBB3 Q27021939-E57C0F89-4C73-4BC2-808E-4F27A44D9429 Q27027729-CD4833CA-F049-460B-AB92-F1D889ACB4C4 Q27700745-76EFDE1C-DD3E-4A64-8DCB-82A34175D1A1 Q28066890-302D8FCB-6A9E-4351-9B3D-8D0B61A863E7 Q28075816-A469EB3B-A95E-418F-84D9-A9EAA1FE5D6B Q33437811-9CD29C9B-BA82-42C5-84B7-1690B99914D2 Q33621610-595FB97C-2174-4C4C-981C-344249A00D68 Q33691970-03BC60EA-9ECC-4058-A290-28BC15D9AED8 Q33992425-021EC5C4-6BD0-4D80-98D9-B14D71277290 Q34041792-3D2628E8-383A-43D1-9DEC-9299D66C8ADA Q34046505-7B7C3C9C-8206-4BDE-AB08-F5CFEC43C51E Q34517676-BD160BC9-6080-4E23-A751-E0FEFEBF0F76 Q34789569-34C854A1-60F0-4B25-ACDC-37D260D873A6 Q35175289-0A05FDBA-DC97-4FFA-A836-4EDFFF4AEE17 Q35788245-2AA3F410-D6D1-437B-9A75-B0C3B03F3AD3 Q35834665-D2721EAE-FBE5-4E76-B3B8-55EE96A399DB Q36253378-2F4170B1-AC02-4C81-9300-80885EC9275C Q36386891-E9FC87D6-5F23-4AD4-9B43-794F3233BB99 Q36519358-2075BC67-6C79-4BF1-9EED-FD011F5BCA84 Q36547199-C52393FD-64C1-4256-9D25-416CE62083C0 Q36830759-8D3F53C4-EE28-4C7B-BF3C-7CC9D91976BA Q37035836-E95F1137-3D23-4202-8016-8EBF23ECDB0D Q37058104-10E9F830-A7B6-4755-BCF0-9EE42281DCCC Q37201423-2D600A52-47F5-4AD5-BE92-70E0CEC8C23D Q37576033-36C869ED-DECF-4C93-8D8A-4CC84CD96C24 Q37587956-9A4EF713-665D-4059-8D97-FF9024E17F86 Q37666309-867A00A6-2D64-44AB-9773-787DF042BD6C Q37723469-FC7873C3-128B-43C5-AA22-9B0CBA58895A Q38170496-994EDBCE-8FAC-4125-AC08-1FEC80D3C393 Q38171067-0283EB57-E756-4787-9783-8010F67954E2 Q38178359-C0EE57E4-D31F-4A64-92FD-14CF0C6AA17A Q38237360-CD0EAE81-7EDE-4DD5-8151-05FD24B580A2 Q38246639-A54CD705-BF62-419B-ACD7-AB093A197871 Q38289029-74D04119-C67B-4769-AC99-1AD2CD83D1AC Q38365867-34B2B7D7-5D44-4D6C-AF73-BC3C29040F7B

P2860

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.

http://www.wikidata.org/entity/Q36778126

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

B-cell maturation antigen is a ...... l therapy of multiple myeloma.

@ast

B-cell maturation antigen is a ...... l therapy of multiple myeloma.

@en

type

label

B-cell maturation antigen is a ...... l therapy of multiple myeloma.

@ast

B-cell maturation antigen is a ...... l therapy of multiple myeloma.

@en

prefLabel

B-cell maturation antigen is a ...... l therapy of multiple myeloma.

@ast

B-cell maturation antigen is a ...... l therapy of multiple myeloma.

@en

P1433

Q36778126-B29BAE28-4CC8-4818-9B9F-72C87312CDEE

P1476

Q36778126-0A456032-4A5C-4EE8-BA84-916B45BA1677

P2093

Q36778126-0654F8DB-8960-4D34-AAC2-D21019ED9AFB

Q36778126-1435BF51-AA52-4AEE-9253-48F15086B601

Q36778126-195E9D4A-ABB1-453E-9706-397A10D4BCA6

Q36778126-227B5CC6-12F9-4F63-A4CB-881B5328D395

Q36778126-2F0CD40A-DB5E-4A1E-B890-92B99F6FFABA

Q36778126-39655E8C-AEC8-4769-B89E-7A2DF8DE1C76

Q36778126-6576CC4D-3638-4D46-8201-6DCFF10DC3F8

Q36778126-7C77ACEA-F128-4420-98CA-9C82548B6A44

Q36778126-C7F9B142-97D7-4D2F-92D8-18332E6A1DE4

P2860

Q36778126-079E2498-E9FC-441D-B379-824CB122E6CE

Q36778126-0A9819CA-A71E-463C-BFFF-18FC22EE8D07

Q36778126-0ACF581A-595B-4031-9AA7-59DDC1B52A02

Q36778126-0C611560-2C93-4E1C-B02D-7592D3E64540

Q36778126-0D1EEEC2-4DCC-4173-810A-D8905F477CC7

Q36778126-10ED7969-2391-4D49-80E9-C4A60CBC7994

Q36778126-22EFDE2A-F69A-4707-A967-A3B54C564AAD

Q36778126-2F006FEF-1965-4E8F-A610-2682727ECA66

Q36778126-2F5793F4-B9EA-46CC-A35E-69C6E5132E3A

Q36778126-36CC0F25-C50A-4A2B-B0B4-E5DC8F931ECA

P304

Q36778126-40721D3C-B3F0-4647-A130-CBC6052D7FFE

P31

Q36778126-EC3BF704-4689-430A-84CE-C5F90F617293

P356

Q36778126-E27C9439-0B26-4860-B1B9-CA9B772B1F9A

P407

Q36778126-517B4689-F4C4-4B08-913E-F435E568FD1A

P433

Q36778126-607CF5D6-3C04-4B78-80F8-67370BFA54C3

P478

Q36778126-62FF0C68-4CD8-409E-8BBC-958E1AEAF632

P577

Q36778126-244EE424-2828-4833-B9F5-9E6D039CD694

P698

Q36778126-22AD1BD0-2DFF-416D-A91E-E6F5539C5BCF

P932

Q36778126-F78142C9-E5F2-4984-91C1-E0665D7FCACF

P356

1078-0432.CCR-12-2422

P1433

Clinical Cancer Research

P1476

B-cell maturation antigen is a ...... l therapy of multiple myeloma.

@en

P2093

Frances T Hakim

http://www.w3.org/2001/XMLSchema#string

James N Kochenderfer

http://www.w3.org/2001/XMLSchema#string

Jeremy J Rose

http://www.w3.org/2001/XMLSchema#string

Mark Raffeld

http://www.w3.org/2001/XMLSchema#string

Moses O Evbuomwan

http://www.w3.org/2001/XMLSchema#string

Robert O Carpenter

http://www.w3.org/2001/XMLSchema#string

Ronald E Gress

http://www.w3.org/2001/XMLSchema#string

Shicheng Yang

http://www.w3.org/2001/XMLSchema#string

Stefania Pittaluga

http://www.w3.org/2001/XMLSchema#string

P2860

The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed

A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor

Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival

BCMA is essential for the survival of long-lived bone marrow plasma cells

B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

P304

2048-2060

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-2422

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23344265

http://www.w3.org/2001/XMLSchema#string

P932

3630268

http://www.w3.org/2001/XMLSchema#string